PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,275,434
|
factor affect covid test behaviour among popul south western nigeria object object studi assess factor affect test behaviour amongst popul ondo lago state method cross section studi involv individu consid elig covid test local govern lago ondo state nigeria conduct april june respond select use simpl random sampl close end questionnair administ use digit survey platform known surveycto data analyz use r result lago state femal male ondo femal male chi squar test associ reveal socio demograph factor signific associ test pattern educ level lago none ondo test behavior associ test pattern includ awar nearbi covid test center internet access knowledg preexist condit anoth member famili test posit signific level conclus knowledg pre exist condit knowledg covid symptom know go symptom signific associ test willing test
|
D007722;D000086382
|
T053;T067;T047
|
36,275,433
|
associ live area childhood respiratori diseas mortal adulthood object studi examin associ characterist urban area futur respiratori diseas mortal examin whether type live area childhood associ caus respiratori diseas mortal adulthood method total japanes particip age year old complet lifestyl questionnair includ type childhood live area cox proport hazard regress model use calcul multivari hazard ratio hrs confid interv cis caus respiratori diseas mortal result live larg citi area childhood associ higher risk caus mortal hr ci respiratori diseas mortal hr ci compar rural remot area excess risk caus respiratori diseas mortal primarili found industri area among men respect multivari hrs ci ci conclus elimin childhood health hazard associ live industri area suggest reduc risk mortal respiratori diseas adulthood
|
D012140;D012120
|
T047
|
36,275,432
|
real time analysi predictor covid infect spread countri european union new tool object real time data analysi pandem crucial paper aim introduc novel interact tool call covid predictor tracker use sever sourc covid data allow examin develop time across countri exemplifi investig relat effect vaccin non pharmaceut intervent covid spread method combin indic global covid trend impact survey john hopkin univers world data european centr diseas prevent control nation center environment inform eurostat use random forest hierarch cluster rank correl predict covid case result found among non pharmaceut intervent mask usag strong effect percentag peopl vaccin least follow countri specif measur lock down countri similar characterist share rank infect predictor gender age distribut healthcar expenditur cultur particip interact restrict measur conclus includ time awar machin learn model covid infect dashboard allow disentangl rank predictor covid case per countri support polici evalu open sourc tool updat daili continu data stream expand pandem evolv
|
D000086382
|
T047;T067
|
36,275,431
|
central adipos indic maintain stronger associ risk hypertens prospect cohort studi southwest china object studi link obes increas risk hypertens optim adipos indic predict hypertens remain controversi comprehens explor correl bodi mass index waist circumfer wc waist height ratio whtr long term weight wc chang hypertens adult popul southwest china method studi particip township district follow year guizhou popul health cohort studi use pearson correl coeffici combin dunn clark z test zou confid interv test receiv oper characterist roc analys multivari cox proport hazard regress adjust demograph characterist lifestyl habit diseas histori lipid inform particip result baselin central adipos indic wc whtr closer associ hypertens bmi long term wc chang predict hypertens compar weight chang studi popul conclus central adipos indic maintain stronger associ risk hypertens hint import wc manag precaut hypertens
|
D050154;D006973
|
T047;T032
|
36,275,430
|
qualiti life updat psychometr properti new norm valu repres german sampl focus socioeconom mental health object qualiti life qol increas use indic health research aim paper updat psychometr valid new standard german version eurohi qol use sampl german general popul assess studi focus socio econom characterist anxieti depress major indic mental health method item eurohi qol econom instrument self assess result statist test reveal good psychometr properti gender age group specif norm valu calcul eurohi qol show good discrimin valid anxieti depress symptom particip without clinic relev score depress anxieti report signific higher qol multipl regress analysi show unemploy younger age live partner immigr background import predictor lower qol wherea higher incom live one home high level educ predict higher qol conclus eurohi qol confirm econom reliabl instrument assess qol german general popul
|
D011788;D008603
|
T078;T041
|
36,275,397
|
quantif gait stabil inclin declin walk respons requir coeffici friction dynam postur index studi aim investig gait stabil respons inclin declin walk various surfac inclin angl term requir coeffici friction rcof postur stabil index psi center pressur cop center mass com distanc custom platform differ surfac inclin design twenti three male volunt particip walk inclin platform inclin process repeat declin platform well qualysi motion captur system use captur collect trajectori motion ten reflect marker attach subject export visual three dimension softwar execut matlab obtain rcof psi well dynam psi dpsi cop com distanc paramet accord result inclin walk initi contact rcof affect inclin howev affect peak ground reaction forc grf start toward walk condit affect psi found anterior posterior psi apsi even low inclin inclin declin walk hand dpsi affect walk condit furthermor cop com distanc affect declin walk anterior posterior direct find research indic order decreas risk fall manag inclin demand suitabl walk strategi improv safeti measur appli slope walk particular declin anterior posterior orient studi also provid addit understand best inclin walk techniqu secur practic inclin locomot
|
D004856;D005684
|
T033;T040
|
36,275,396
|
butorphanol adjuv ropivacain adductor canal block total knee arthroplasti patient random doubl blind studi object studi observ effect butorphanol adjuv ropivacain adductor canal block acb postop analgesia patient undergo total knee arthroplasti tka
|
D019645;D009407
|
T061
|
36,275,035
|
meta analysi activ tuberculosi gene express ascertain host direct drug target multi drug resist tuberculosi still remain major public health crisi global emerg newer activ tuberculosi diseas requir prolong treatment time adher therapi till complet necessit search newer therapeut target human host factor current work util statist meta analysi human gene transcriptom activ pulmonari tuberculosi diseas obtain six public dataset meta analysi result identif signific differenti express gene deg activ tuberculosi diseas gene ontolog go analysi reveal gene major contributor immun respons pathway enrich analys identifi various human canon pathway relat infecti diseas addit comparison deg tuberculosi genom wide associ studi gwas dataset reveal presenc genet variant proxim analysi protein interact network human mycobacterium tuberculosi host direct drug target interact network led new candid drug target drug repurpos studi current work shed light host gene pathway enrich activ tuberculosi diseas suggest potenti drug repurpos target host direct therapi
|
D014376;D009169;D014397
|
T047;T007
|
36,275,034
|
larg gap attitud action tuberculosi prevent treatment among tuberculosi relat healthcar worker eastern china healthcar worker hcws high risk latent tuberculosi infect ltbi occup exposur attitud behavior frontlin tuberculosi tb relat hcws toward prevent treatment ltbi eastern china remain unknown studi aim explor attitud actual behavior tb relat hcws toward tb prevent treatment tpt analyz relev factor influenc attitud hcws stratifi random sampl tb design hospit select zhejiang provinc china tb relat hcws select hospit recruit answer questionnair test ltbi tb interferon gamma releas assay tpt use assess two year survey univari analysi binari logist regress model use analyz factor influenc tpt intent hcws total tb relat hcws recruit tb design hospit show posit attitud toward tpt rest reluct treat posit ltbi prophylact binari logist regress analysi reveal factor influenc attitud hcws main educ level household incom histori alcohol consumpt workplac igra test found hcws test posit ltbi peopl refus treatment drug side effect follow belief treatment ineffect want wait onset diseas much troubl take medic accord result follow survey one hcws underw tpt consist rate attitud behavior studi reveal differ attitud toward tpt among tb associ hcws eastern china larg gap attitud actual action manag hcws ltbi still need strengthen
|
D055985;D014376
|
T047
|
36,275,033
|
vitamin alter macrophag phenotyp endosom traffick marker dairi cattl natur infect mycobacterium avium subsp paratuberculosi macrophag import host defens cell rumin paratuberculosi john diseas jd chronic enter caus mycobacterium avium subsp paratuberculosi map classic macrophag function pathogen traffick degrad antigen present interrupt mycobacteri infect immunolog stimul hydroxyvitamin oh dihydroxyvitamin oh enhanc bovin macrophag function present studi aim investig role vitamin macrophag phenotyp endosom traffick map monocyt deriv macrophag mdms cultur jd jd subclin jd clinic infect cattl mdms pre treat ngml oh ngml oh incub hrs map multipl infect moi vitro map infect upregul pro inflammatori cd downregul resolutionrepair cd vitamin general decreas cd increas cd express furthermor earli endosom marker rab upregul across stage paratuberculosi infect follow vitro map infect howev rab reduc map activ mdms jd subclin jd clinic cow compar healthi control rab express decreas control clinic cow follow mdm infect map form vitamin reduc rab express infect mdms jd control cow oh decreas rab express jd jd subclin anim regardless map infect vitro vitamin promot phagocytosi mdms jd jd clinic cow treat either vitamin analog result studi show exogen vitamin influenc macrophag mm polar rab gtpase express within mdm cultur
|
D016927;D010283;D002418
|
T047;T007
|
36,275,032
|
identif character extracellular vesicl red cell infect babesia divergen babesia microti babesiosi zoonosi import blood born human parasit infect gain attent grow infect rate human transfer anim reservoir babesia repres potenti threat blood suppli asymptomat infect man common blood donor caus sever diseas certain recipi extracellular vesicl ev vesicl releas cell contain complex mixtur protein lipid glycan genet inform shown play import role diseas pathogenesi suscept well cell cell communic immun respons articl report identif character ev releas red blood cell rbcs infect two major human babesia speci babesia divergen vitro cultur vivo b microti mous infect use nanoparticl track analysi show rang vesicl size nm eman babesia infect rbc studi ev context hemoparasit infect complic fact parasit host rbc make releas vesicl extracellular environ howev ev frequenc fold higher babesia infect rbcs uninfect rbcs depend level parasitemia use parasit specif marker abl show ev contain parasit specif marker surfac thus may repres specif proport ev releas infect rbcs within ev popul western blot analysi purifi ev vivo vitro infect reveal sever parasit protein target host immun respons addit microrna analysi show infect rbc ev differ microrna signatur uninfect rbc ev indic potenti role diseas biomark final ev intern rbcs cultur implic potenti role vesicl cellular communic overal studi point multipl function implic ev babesia host interact support potenti ev agent diseas pathogenesi
|
D041001;D001403;D000067128;D035683
|
T026;T123;T204;T114
|
36,275,031
|
challeng develop univers vaccin leptospirosi reveal evalu vaccin candid leptospirosi neglect diseas man anim affect near half million peopl annual caus consider econom loss current human vaccin inactiv whole cell prepar bacterin leptospira spp provid strong homolog protect yet fail induc cross protect immun respons year booster requir serious side effect frequent report vaccin licens use human hand countri novel univers vaccin requir identif conserv surfac expos epitop leptospir antigen outer membran barrel protein b omp meet requir success use vaccin diseas report evalu construct contain protein fragment leptospir b omp previous identifi revers structur vaccinolog cell surfac immunoprecipit three dimension structur leptospir b omp predict tasser surfac expos epitop predict use netmhcii bepipr recombin construct contain region one b omp clone express escherichia coli imac purifi recombin protein adsorb aluminium hydroxid adjuv produc vaccin formul hamster week old vaccin dose contain g recombin protein day interv dose immunoprotect evalu hamster model leptospirosi homolog challeng ed l interrogan serogroup icterohaemorrhagia serovar copenhageni strain fiocruz l vaccin formul immunogen induc signific humor immun respons igg prior challeng four construct induc signific protect p lt steril immun two independ experi howev reproduc subsequ evalu protect p gt lack reproduc seen challeng experi report literatur togeth lack immun correl commerci avail reagent character immun respons suggest hamster may ideal model evalu leptospirosi vaccin highlight need evalu altern model mous
|
D007922;D007919
|
T047;T007
|
36,275,030
|
featur oral microbiom japanes elder peopl teeth non sever periodont condit periodont mainten treatment cross section studi aim present studi character profil divers oral microbiom periodont non sever group teeth comparison sever periodont group elder japanes peopl
|
D064307;D010510;D010518
|
T001;T047;T032;T028
|
36,275,029
|
upcycl known molecul target drug resist tb despit reinvigor effort tuberculosi tb drug discoveri past year relat new drug candid emerg clear util drug resist tb period signific technolog advanc learn around target valu taken place offer opportun assess potenti optim previous discov chemic matter mycobacterium tuberculosi mtb reconsider clinic valid target encumb drug resist assess discard compound program golden age antibiot yield new scaffold target tb uncov class exampl beta lactam previous unappreci util tb leverag valid class target also met success booster technolog effort thwart efflux improv potenti ethionamid spectinomycin class multipl program rescu high valu target avoid cross resist make progress attempt make known class drug target complement effort discov new chemic matter novel target enhanc chanc success discov effect novel regimen drug resist tb
|
D018088;D014376
|
T047
|
36,275,028
|
entamoeba gingivali associ periodont condit chines young patient cross section studi studi investig preval relat abund entamoeba gingivali e gingivali chines young patient differ periodont condit associ subgingiv microbi composit periodont paramet cytokin gingiv crevicular fluid
|
D004747;D010518
|
T047;T204
|
36,275,027
|
evolut mycobacterium tuberculosi drug resist genom era mycobacterium tuberculosi acquir drug resist drug use includ recent introduc clinic practic compar bacteria well conserv genom due role oblig human pathogen adapt nich five ten thousand year featur facilit reconstruct date tuberculosi phylogeni give key insight resist acquir spread global resist new drug occur within five ten year clinic use occur even rapid recent introduc drug case resist confer mutat come fit cost overcom compensatori mutat restor fit wild type bacteria like tuberculosi acquir drug resist maintain limit genom variabl due generat low frequenc within host variat combin ongo purifi select caus loss variant without clear fit advantag howev variant confer advantag drug resist increas preval amongst bacteria within host becom domin clone resist strain transmit lead primari drug resist infect new host mani countri move toward genom method diagnosi tuberculosi infect drug resist import awar implic evolut resist current understand resist confer mutat incomplet target genet diagnost creat select pressur discuss exampl rifampicin resist confer mutat routin cover standard test becam domin final resist new drug bedaquilin delamanid caus individu rare mutat occur across larg mutat genom target detect short time provid statist power genotyp phenotyp correl contrast longer establish drug form backbon drug sensit antituberculosi therapi therefor need differ approach identifi resist confer mutat new drug resist becom widespread abrog use
|
D009169;D014388
|
T047;T007
|
36,275,026
|
oral gut axi salivari fecal microbiom dysbiosi patient inflammatori bowel diseas inflammatori bowel diseas ibd group chronic inflammatori disord fall two main categori crohn diseas cd ulcer coliti uc gastrointestin tract extend mouth anus harbor divers bacteri communiti sever sequenc base studi identifi intestin enrich oral associ bacteria demonstr abil induc intestin inflamm mice suggest intestin pathobiont origin oral caviti particular member genus streptococcus studi aim investig composit salivari fecal microbiom ibd patient n compar healthi control n determin abund common bacteri taxa nich metagenom dna extract saliva fecal sampl rrna gene target sequenc result reveal overal microbi composit saliva signific alter ibd patient compar control subject p genus level veillonella prevotella high abund ibd median respect compar control group respect contrast neisseria streptococcus haemophilus fusobacterium associ healthi gut state regard fecal microbiom ibd group signific higher abund clostridium sensu stricto escherichia shigella compris pathogen bacteria compar control group member bacteri group previous shown posit correl intestin inflamm high express pro inflammatori cytokin disrupt intestin barrier integr addit demonstr increas abund clostridium sensu stricto escherichia shigella also associ signific upregul certain metabol pathway fece ibd group includ bacteri invas epitheli cell streptococcus common genus detect salivari fecal microbiom repres oral gut axi studi use cultur base method isol streptococcus strain saliva well strain fecal sampl control ibd patient respect phylogenet tree streptococci base soda sequenc reveal sever patient specif cluster compris salivari fecal streptococc isol patient belong speci suggest oral caviti endogen reservoir intestin strain
|
D000069196;D015212;D064307
|
T032;T007;T028;T047;T001
|
36,275,025
|
improv accuraci etiolog diagnosi spinal infect metagenom next generat sequenc current use metagenom next generat sequenc mngs new approach identifi organ infecti diseas rare report diagnosi spinal infect studi aim evalu potenti valu mngs etiolog diagnosi spinal infect retrospect studi clinic data patient suspect spinal infect collect electron medic record specimen obtain patient test via mngs assay convent microbiolog test cmts sensit specif mngs cmts calcul use final clinic diagnosi golden standard total patient elig studi mean length stay day regard overal identif pathogen mngs exhibit better perform cmts sever nontubercul mycobacteria fungi bacteria newli discov diagnosi spinal infect sensit specif area curv mngs respect higher cmts hospit discharg c reactiv protein erythrocyt sediment rate white blood cell count patient signific decreas compar hospit p lt show good outcom find may suggest mngs better diagnost accuraci pathogen identif patient suspect spinal infect patient treat ngs guid antimicrobi therapi most seem good outcom
|
D002097;D056186
|
T129;T091;T116
|
36,275,024
|
evolv biolog mycobacterium tuberculosi drug resist tuberculosi caus mycobacterium tuberculosi mtb ancient diseas remain lead caus infecti death mtb evolv drug resist everi antibiot regimen ever introduc great complic treatment lower rate cure menac tb control part world technolog advanc understand antimicrobi resist improv model phenomenon evolv review focus recent research progress support updat model evolut drug resist mtb highlight contribut drug toler path resist influenc heterogen toler resist like remain issu long drug need treat tb howev technolog drive new insight care manag newli develop resourc antimicrobi resist need continu threaten global progress tb done decad
|
D009169;D014388
|
T047;T007
|
36,275,023
|
efficaci evalu probiot combin prebiot patient clinic hypothyroid complic small intestin bacteri overgrowth second trimest pregnanc explor effect probiot combin prebiot clinic hypothyroid pregnanc combin small intestin bacteri overgrowth
|
D019936;D007037
|
T047;T007
|
36,275,022
|
staphylococcus sciuri caus diseas patholog chang hybrid sturgeon acipens baerii acipens schrencki hybrid sturgeon main speci sturgeon cultur china advantag fast growth rate earli sexual matur fertil offspr stabl genet trait may larg number death character superfici hemorrhag liver damag occur sturgeon farm yichang hubei provinc pose signific risk hybrid sturgeon captiv breed isol pathogen bacterium name diseas sturgeon appar symptom pathogen identifi staphylococcus sciuri use rrna gene phylogenet analysi combin biochem identif regress experi show exhibit clinic sign similar diseas sturgeon farm intraperiton inject hybrid sturgeon high throughput sequenc gut microb infect sturgeon show number gut microbi speci decreas infect sturgeon number intestin commens bacteria decreas balanc intestin microorgan disrupt histopatholog section indic mani inflammatori cell congest even necrosi tissu diseas sturgeon analysi blood index reveal increas proport mononuclear cell decreas proport lymphocyt peripher blood diseas sturgeon signific elev serum level aspart aminotransferas alanin aminotransferas wherea alkalin phosphatas total protein albumin globulin decreas diseas sturgeon antimicrobi suscept test demonstr suscept florfenicol enrofloxacin neomycin sulfat studi aim highlight danger staphylococcus sciuri infect hybrid sturgeon cultur provid recommend diagnosi treatment
|
D000469;D000890
|
T121;T126;T116
|
36,275,021
|
promis hiv base virus like particl medic applic new approach aim identifi patient specif drug target address unmet clinic need framework precis medicin strong motiv research worldwid scientist learn protein drive known diseas better abl design promis therapeut approach target protein field nanotechnolog extens explor past year nanoparticl nps emerg promis system target specif deliveri drug virus like particl vlps aris auspici nps due intrins properti lack viral genet materi inabl replic togeth tropism conserv antigen characterist nativ virus prompt extens interest use vaccin deliveri system therapeut andor imag agent owe simplic non complex structur one virus current studi construct vlps human immunodefici virus type hiv typic hiv base vlps use antibodi discoveri vaccin diagnost reagent develop protein base assay review center use hiv base vlps potenti biomed applic
|
D015497;D053758
|
T005;T073
|
36,275,020
|
interrog transmiss dynam trypanosoma cruzi trypanosomatida trypanosomatida triatoma venosa hemiptera reduviida elimin vector transmiss rhodnius prolixus boyac eastern colombia chaga diseas cd parasit zoonosi trypanosoma cruzi endem colombia vector control rhodnius prolixus main domest cruzi vector achiev larg part area histor vector transmiss cd necessari understand ecolog behavior characterist local nativ vector ensur sustain vector control program evalu long term success recent vector control campaign boyac depart colombia use combin strategi entomolog surveil co exist canin surveil ten rural villag within six municip tenza valley region boyac colombia chinavita garagoa guatequ somondoco sutatenza tenza histor report r prolixus secondari vector collect triatomin canin whole blood analyz cruzi infect genotyp triatomin bug specimen evalu blood meal sourc canin serolog perform use two distinct antibodi assay total triatoma venosa collect activ search domest peridomest habitat natur infect preval four feed sourc identifi human dog rat hen frequenc infect observ two independ serolog test cruzi dna detect dog tcisylvat dtu detect result suggest venosa present eco epidemiolog characterist maintain transmiss cruzi tenza valley speci reinfest interven household activ role domest peridomest transmiss cruzi due infect rate feed behavior therefor speci consid epidemiolog relev vector control strategi moreov need human serolog studi close risk expos
|
D014224;D014349;D012239;D014351;D014355
|
T047;T204
|
36,275,019
|
epidem risk factor carbapenem resist klebsiella pneumonia infect effect earli prognosi liver transplant carbapenem resist klebsiella pneumonia crkp infect remain major caus morbid mortal earli stage post liver transplant lt
|
D007710;D016031;D006528;D008113;D000073182
|
T061;T047;T191;T007
|
36,275,018
|
immunolog evalu recombin prrsv gp gp dna vaccin vivo porcin reproduct respiratori syndrom virus prrsv threat health pig worldwid commerci avail vaccin offer limit protect prrsv infect necessari develop effect dna vaccin immunolog effect dna vaccin three adjuv examin pig susscrofa domestica challeng prrsv dna vaccin encod prrsv gp gp formul serum specif neutral antibodi il ifn il il cd cdt lymphocyt health status histopatholog viral load determin result show use adjuv led higher level neutral antibodi lower viral load pig compar adjuv neutral antibodi titer pvax gpa pvax gpa group reach peak dpi maximum concentr il pgml pvax gpa group dpi ifn concentr pvax gpa group pgml pvax gpa group show highest il il express peak pgml pgml respect found formul demonstr benefici immun outcom studi provid altern vaccin protect pig prrsv
|
D019316;D019444;D019318;D014765
|
T129;T121;T005;T114;T047
|
36,275,017
|
hypoxia induc factor alpha regul neutrophil recruit fungal elicit granulomat inflamm chronic pulmonari aspergillosi cpa devast diseas increas preval worldwid characterist granulomat like inflamm pose major setback effect antifung therapi limit drug access fungi inflammatori lung structur report sever hypox nevertheless under mechan wherebi process contribut fungal persist remain larg unknown hypoxia induc factor alpha hif besid major cellular respons regul hypoxia known central immun modul use model aspergillus fumigatus airway infect myeloid restrict hif knock mhif mice replic complex structur resembl fungal granuloma evalu contribut hif antifung immun diseas develop found fungal elicit granuloma mhif mice signific smaller area along extens hyphal growth increas lung fungal burden phenotyp associ defect neutrophil recruit increas neutrophil death therefor highlight central role hif mediat regul neutrophil function pathogenesi chronic fungal infect result hold promis improv capac manag progress chronic fungal diseas open new avenu addit therapeut target nich intervent
|
D000935;D001228
|
T121;T047;T195
|
36,275,016
|
protein domain depend vesicul lipoprotein protein import cell wall synthesi fit human respiratori pathogen haemophilus influenza human pathogen haemophilus influenza caus respiratori tract infect common associ prolong carriag patient chronic obstruct pulmonari diseas product outer membran vesicl omv ubiquit phenomenon observ gram negat bacteria includ h influenza omv play import role various interact human host neutral antibodi complement activ spread antimicrobi resist upon vesicul certain protein found omv protein retain cell membran mechan phenomenon fulli elucid employ mass spectrometri studi vesicul fate protein outer membran function group protein differenti distribut cell surfac omv despit suppos periplasm outer membran locat found peptidoglycan synthas activ lipoprotein lpoa accumul omv relat membran fraction mutant devoid lpoa lost fit reveal growth electron microscopi furthermor high pressur liquid chromatographi disclos lower concentr peptidoglycan lpoa defici h influenza compar parent wild type bacterium use lpoa mneongreen fusion protein fluoresc microscopi observ lpoa enrich foci cell envelop locat septum cell divis defin fate lpoa c termin truncat lpoa variant construct found lpoa c termin domain promot optim transport omv reveal flow cytometri taken togeth studi highlight import lpoa h influenza peptidoglycan biogenesi provid novel insight cell wall integr omv product
|
D006193;D000890
|
T121;T007
|
36,275,015
|
metagenom next generat sequenc indic precis pathogen patient pulmonari infect retrospect studi time identif causat pathogen import diagnosi treatment pulmonari infect metagenom next generat sequenc mngs novel approach pathogen detect direct sequenc nucleic acid specimen provid wide rang microbi profil purpos studi evalu diagnost perform mngs bronchoalveolar lavag fluid balf patient suspect pulmonari infect
|
D060085;D011014;D009696
|
T123;T047;T050;T114
|
36,274,995
|
year retrospect claim analysi oral corticosteroid use health condit newli diagnos medicar ffs patient copd analyz popul level administr claim data medicar fee servic ffs beneficiari provid insight system oral corticosteroid oc use pattern associ health condit acut event among patient newli diagnos chronic obstruct pulmonari diseas copd
|
D029424;D003924;D006973
|
T047
|
36,274,994
|
bronchodil respons defin ersat criteria patient asthma well chronic obstruct pulmonari diseas ersat interpret strategi routin lung function test posit bronchodil respons bdr updat chang relat predict valu forc expiratori volum second fev forc vital capac fvc aim explor differ ersat criteria appli patient asthma well chronic obstruct pulmonari diseas copd
|
D029424;D001249
|
T047
|
36,274,993
|
updat perspect role biomechan copd consider clinician patient chronic obstruct pulmonari diseas copd demonstr extra pulmonari function declin increas preval fall biomechan offer insight function declin examin mechan abnorm movement pattern review discuss biomechan function outcom muscl mechan breath mechan patient copd well futur direct clinic perspect patient copd demonstr chang postur sway quiet stand compar control deficit exacerb sensori inform eg eye close manipul stand balanc disrupt perturb patient copd slower return baselin muscl activ differenti control walk patient copd appear adopt gait pattern may increas stabil eg shorter wider step decreas gait speed addit alter gait variabl biomechan muscl mechan ie tension extens elast irrit alter copd well document relat articl investig properti hand dyssynchron motion abdomen rib cage breath well document patient copd newer biomechan technolog allow estim region compartment lung volum activ exercis well respiratori muscl activ breath futur direct biomechan analys copd trend toward wearabl sensor big data cloud comput offer uniqu opportun well challeng advanc analyt sensor data offer insight health system quantifi complex fluctuat pattern movement healthi system demonstr flexibl thus adapt chang condit biomechan may offer clinic util predict day readmiss identifi diseas sever patient monitor biomechan complementari assess captur patient well capabl
|
D029424
|
T047
|
36,274,992
|
copd lung cancer mechan link diagnosi treatment prognosi mani studi prove pathogenesi chronic obstruct pulmonari diseas copd lung cancer relat may caus affect certain extent fact chang chronic airway obstruct continu impact screen treatment prognosi lung cancerin comprehens review outlin link heterogen copd lung cancer find factor gene express genet suscept epigenet smoke epitheli mesenchym transform emt chronic inflamm oxid stress injuri may play role process although relationship two diseas larg determin method prevent lung cancer copd patient still limit earli diagnosi still key better prognosi thus necessari establish intuit screen evalu criteria find suitabl biomark lung cancer screen high risk popul copd studi indic copd may chang efficaci anti tumor therapi affect respons lung cancer patient immun checkpoint inhibitor ici lung cancer patient copd standard manag copd improv prognosi treatment lung cancer patient copd individu comprehens precis process develop new target new strategi molecular target therapi may breakthrough diseas treatment futur
|
D008175;D029424
|
T047;T191
|
36,274,975
|
advanc frontotempor dementia ftd neuropatholog molecular genet morbid frontotempor dementia ftd one preval dementia praccox second alzheim diseas ad differ ad ftd rapid cours higher mortal ftd yet fulli understood term etiolog pathogenesi genet factor believ involv paper commit provid comprehens overview ftd aspect neuropatholog featur relev molecular genet advanc would insight research search novel approach ftd diagnosi treatment
|
D057180;D000544
|
T047;T048
|
36,274,974
|
lncrna il ra attenu lps induc sepsi via mir pprkcg mediat mapk signal pathway sepsi repres syndrom system inflammatori respons most result infect various pathogen microorgan character uncontrol infect respons organ lead life threaten organ dysfunct long noncod rna lncrna compet endogen rna affect bind microrna mirna mrna thus influenc develop sepsi studi base transcriptom data geo databas screen differenti express lncrnas construct lncrna mirna mrna network pathway il ra mir pprotein kinas c gamma prkcg coexpress network success sort effect network lps induc sepsi model thp cell also verifi cck scratch elisa western blot qrt pcr assay correspond bind site mir p il ra mir p prkcg verifi use dual luciferas gene report assay respect compar control si il ra signific inhibit cell viabil migrat abil thp level proinflammatori factor il il tnf secret mark decreas express il ra prkcg p mekk p jnk mark reduc addit il ra could target bind mir p inhibit express mir p could also bind prkcg experi demonstr il ra attenu sepsi respons mir pmapk pathway compet endogen rna cerna network may potenti approach predict combat sepsi
|
D035683;D062085;D018805;D011493;D053722
|
T123;T116;T192;T126;T114;T047;T046
|
36,274,973
|
associ altast muscl mass patient type diabet mellitus alanin aminotransferaseaspart aminotransferas altast ratio thought relat metabol disord insulin resist type diabet mellitus tdm high risk popul low muscl mass studi perform evalu associ altast muscl mass subject tdm
|
D003924
|
T047
|
36,274,972
|
distinguish valu benign nevus melanoma use machin learn meta analysi systemat review melanoma common human malign primarili diagnos visual begin initi clinic screen follow potenti dermoscop analysi biopsi histopatholog examin aim systemat review perform qualiti machin learn base method distinguish melanoma benign nevus relev literatur
|
D008545;D009506
|
T191
|
36,274,818
|
hsa mir p inhibit wnt catenin signal human corneal epitheli stem cell earlier studi identifi hsa mir p high express mirna enrich corneal epitheli stem cell cesc studi aim understand molecular regulatori function hsa mir p associ mainten stem cesc
|
D060449;D035683
|
T123;T044;T114
|
36,274,817
|
dopachrom tautomeras retinoblastoma specif gene proxim promot preferenti activ human retinoblastoma cell retinoblastoma rb malign childhood intraocular tumor current treatment option rb undesir side effect comprehens understand gene express human rb essenti develop safe effect new therapi
|
D019746;D019572;D012175
|
T191;T126;T116
|
36,274,816
|
oral administr dual et et b receptor antagonist promot neuroprotect rodent model glaucoma glaucoma neurodegen diseas associ elev intraocular pressur character optic nerv axon degener cup optic disc loss retin ganglion cell rgcs endothelin et system vasoact peptid et et et g protein coupl receptor et et b receptor shown contribut pathophysiolog glaucoma purpos studi determin whether administr endothelin receptor antagonist macitentan neuroprotect rgcs optic nerv axon administ onset intraocular pressur iop elev ocular hypertens rat
|
D018696;D019636;D005901;D009798
|
T121;T047;T169
|
36,274,777
|
use learn analyt examin differ assess form continu versus episod supervisor famili medicin resid assum need continu supervis within compet base medic educ despit evid come undergradu medic educ rather graduat medic educ gme context evid gap must address justifi time effort need redesign gme program support continu supervis
|
D005194;D007396
|
T065;T091;T097
|
36,274,776
|
associ covid pandem va resid fellow train satisfact futur va employ mix method studi covid pandem alter learn experi resid fellow worldwid includ us depart veteran affair va va largest train provid unit state understand va traine experi vital understand pandem impact graduat medic educ nationwid addit understand pandem potenti impact futur employ allow better understand futur disrupt suppli physician
|
D000086382;D007396
|
T065;T047;T097;T067
|
36,274,775
|
analysi underrepres medicin away rotat scholarship surgic specialti underrepres medicin uim visit student clerkship scholarship provid opportun support divers although scholarship becom popular initi recruit divers surgic applic thorough analyz regard program offer scholarship characterist scholarship uim scholarship opportun dispar may exist depend locat fund reput program size among differ specialti
|
D007396;D013043
|
T065;T091;T097
|
36,274,774
|
crush thing understand resid assess burden compet base curriculum compet base medic educ cbme expect increas workload assess graduat train program support develop compet learn condit anticip improv provis tailor learn experi frequent low stake assess canada adopt approach cbme call compet design cbd howev process implement learner anxieti assess burden increas unexpect mitig unintend consequ need stronger understand resid assess burden emerg function
|
D007396
|
T065;T097
|
36,274,773
|
ethnic racial differ rate medic student standard letter evalu sloe standard letter evalu sloe stratifi assess emerg medicin em bound medic applic howev bias sloe particular regard race ethnic underexplor area
|
D007396;D013337;D004635
|
T065;T091;T097
|
36,274,770
|
evalu teach health center graduat medic educ model year practic base outcom opportun sinc teach health center graduat medic educ thc gme program sought expand access care train resid safeti net set
|
D007396;D002047
|
T065;T121;T097;T109
|
36,274,769
|
reflect discuss exercis racial justic equiti resid valuabl perspect divers equiti medic train yet mani graduat medic educ curricula lack dedic activ focus issu
|
D007396
|
T065;T097
|
36,274,766
|
theoret framework medic educ use systemat review ophthalmolog educ research creat theori chang model theoret framework provid len examin question interpret result howev underutil medic educ
|
D009885;D007396;D004501
|
T065;T091;T097
|
36,274,765
|
racial bias emerg medicin standard letter evalu studi compon resid applic shown evid racial bias standard letter evalu sloe assess measur emerg medicin em resid applic specialti opt use sloe place narrat letter recommend understand bias standard assess essenti
|
D007396;D063505;D004635;D013337
|
T065;T054;T091;T097
|
36,274,763
|
real time dual video conferenc simul tracheostoma matur resid interview report dexter test done distanc telecommun set resid applic evalu
|
D007396;D010036
|
T065;T091;T097
|
36,274,667
|
knowledg attitud regard donat milk socio demograph predictor healthcar provid tabriz cross section studi donat milk best choic infant receiv breast milk mother research studi evalu knowledg attitud healthcar provid regard milk donat examin socio demograph predictor tabriz iran
|
D007722;D006282
|
T053;T097
|
36,274,666
|
stroke survivor famili caregiv experi health inform seek qualit studi stroke signific unpredict event affect physic mental function use approach return normal life seek health inform studi aim explor experi health inform seek stroke survivor famili caregiv
|
D017028;D020521
|
T099;T098;T097;T047
|
36,274,664
|
preval misophonia relationship obsess compuls disord anxieti depress undergradu student shiraz univers medic scienc cross section studi misophonia sever emot respons repetit sound disord may limit person communic reduc hisher abil disrupt hisher social person life studi aim determin preval misophonia relationship obsess compuls disord anxieti depress undergradu student shiraz univers medic scienc
|
D003863;D009771
|
T184;T048
|
36,274,663
|
women empower status menopaus transit cross section studi women empower status menopaus transit great import due increas trend life expect popul age studi conduct evalu empower status women menopaus transit gonabad iran
|
D014933;D000079102
|
T064;T054;T080
|
36,274,662
|
effect malva sylvestri cream episiotomi pain heal random control clinic trial episiotomi one common procedur childbirth iran caus pain discomfort scar perineum studi aim pursu effect malva sylvestri cream episiotomi pain heal
|
D004841;D028501
|
T061;T002
|
36,274,660
|
design social market base intervent promot sun protect behavior among urban adolesc boy studi protocol skin cancer one prevent diseas purpos studi describ social market base intervent design protocol promot sun protect behavior among adolesc boy live urban area yasuj south west iran
|
D040241;D012878
|
T191;T057
|
36,274,624
|
applic challeng liquid chromatographi tandem mass spectrometri matern child health due ultra high sensit specif throughput liquid chromatographi tandem mass spectrometri lc msms becom import analyt tool clinic laboratori quantifi various small molecul vitamin bile acid steroid intern metabolit relev matern diseas effect mean screen diagnos diseas prevent medicin lc msms wide use matern child health contribut reduct incid matern child diseas prematur morbid mortal present lc msms emerg power platform laboratori test china face challeng opportun articl repres applic field matern child health summar discuss along major hurdl lc msms clinic recognit implement
|
D053719;D000067576
|
T063;T058;T078
|
36,274,623
|
research progress infiltr zone microvascular invas hepat alveolar echinococcosi hepat alveolar echinococcosi ae parasit diseas biolog characterist similar malign tumor obvious clinic symptom earli stage patient complic jaundic ascit gastrointestin bleed see doctor time cours diseas advanc stage addit incomplet resect ae lesion lead high postop recurr rate serious impact physic mental health patient base summari latest research home abroad analysi blood suppli microvascular invas vascular growth factor express infiltr zone adjac lesion hepat ae articl deep understand occurr develop process hepat ae aim better guid clinic practic improv qualiti life patient
|
D004444
|
T047
|
36,274,622
|
recent progress aptasensor tumor exosom associ protein detect exosom phospholipid bilay membran enclos vesicl releas cell diamet nm exosom direct reflect physiolog function state secretori cell particip materi transport inform communic cell great signific biomark earli tumor diagnosi treatment evalu mani detect method exosom among aptasensor technolog properti low price easi oper fast respons high sensit remark specif help tumor patient find diagnos treat earli improv surviv rate provid import basi evalu prognosi seven type common aptasensor fluoresc electrochem colorimetr luminesc later flow strip surfac enhanc raman scatter surfac plasmon reson sensor differ aptasensor differ characterist articl focus research progress sever common aptasensor tumor exosom detect
|
D055354;D009369;D015374
|
T026;T191;T059;T075
|
36,274,621
|
consider possibl etiolog mechan countermeasur sever acut hepat unknown origin children sinc april sever acut hepat unknown origin children spread countri region around world case report sinc sever acut hepat unknown origin involv wide rang area high rate critic identifi etiolog establish effect prevent diagnost therapeut measur soon possibl studi discuss possibl mechan countermeasur sever acut hepat unknown origin children specul occurr recent sever acut hepat might relat adenovirus adeno associ virus infect covid epidem differ hla polymorph among differ race might relat fact report case common europ unit state base current avail evid preliminarili judg risk larg scale outbreak sever acut hepat unknown origin children would low china persist awar vigil etiolog still need
|
D000086382;D006505
|
T047;T067
|
36,274,620
|
understand behaviour social driver vaccin uptak introduct implic world health organ posit paper may world health organ posit paper understand behaviour social driver vaccin uptak besd publish review introduc besd toolkit intervent increas vaccin uptak offer posit recommend base immun practic posit paper implic improv vaccin coverag china promot besd toolkit local integr measur monitor besd multisector routin effort enhanc divers profession immun practition design carri implement research scientif
|
D017589;D014612
|
T129;T058;T121;T116
|
36,274,619
|
serotyp method streptococcus pneumonia serotyp streptococcus pneumonia identifi one bottleneck problem pneumococc diseas diagnosi surveil develop pneumococc vaccin effect evalu pneumococc vaccin three categori approach pneumococc serotyp discuss includ phenotyp base anti serum biochem type base pneumococc capsular characterist genotyp base pneumococc capsular locus sequenc review develop applic differ serotyp pneumococcus provid guidanc pneumococc diseas prevent control
|
D011008;D011014
|
T047;T050
|
36,274,618
|
analysi scrap situat covid vaccin suzhou citi analyz usag loss covid vaccin ten district suzhou citi decemb april result show loss rate suzhou citi loss rate pre fill packag covid vaccin higher vial packag loss rate packag lowest vial packag loss rate kind covid vaccin stabl inocul unit lowest recommend distribut vial packag covid vaccin central vaccin reduc loss covid vaccin
|
D000086663;D000086382
|
T200;T047;T067
|
36,274,617
|
associ awar nutrit fact panel prepackag food purchas behavior among resid object explor associ cognit nutrit fact panel prepackag food purchas behavior among resid six provinc china method use multi stage sampl method adult age select western region sichuan eastern region guangdong jiangsu beij central region henan northeastern region heilongjiang china juli march socio demograph characterist particip cognit nutrit fact panel prepackag food purchas behavior collect questionnair multivari binari logist regress model use analyz associ cognit nutrit fact panel prepackag food purchas behavior result age subject year among femal knew nutrit fact panel would read purchas could understand bought prepackag food week result multivari analysi show adjust relev confound factor compar particip know read nutrit fact panel group know read like buy type prepackag food least week p compar particip read understand nutrit fact panel group read understand less like buy type prepackag food least week p conclus correl cognit nutrit fact panel prepackag food purchas behavior among resid
|
D005515;D005502
|
T068;T168;T057
|
36,274,616
|
analysi epidemiolog characterist bacillari dysenteri multipl onset henan provinc object understand epidemiolog characterist bacillari dysenteri multipl onset henan provinc method report case bacillari dysenteri includ confirm case clinic diagnos case henan provinc januari decemb collect china nation diseas supervis inform manag system main inform includ gender age home address date onset date diagnosi interv two episod case day judg two episod incid characterist bacillari dysenteri patient two case henan provinc analyz region distribut map case drawn use arcgi softwar result total case bacillari dysenteri report henan provinc cumul incid rate case two attack incid recurr case bacillari dysenteri increas year year trend p signific differ incid two case differ sex p signific differ incid among differ age group p incid two case age group relat high shortest time interv onset diseas day longest day q q day compar healthi peopl histori bacteri diseas higher risk develop bacillari dysenteri rr ci conclus proport patient multipl onset show increas trend age differ
|
D004405
|
T047
|
36,274,615
|
influenc meteorolog factor sar cov transmiss evid laboratori epidemiolog studi sar cov infect million peopl worldwid caus million death emerg novel variant made epidem rebound mani place meteorolog factor affect epidem spread chang virus activ transmiss dynam paramet host suscept paper systemat analyz current avail laboratori epidemiolog studi associ meteorolog factor covid incid order provid scientif evid futur epidem control prevent well develop earli warn system
|
D000086402;D000086382
|
T005;T067;T047
|
36,274,614
|
review heat wave earli warn base popul health risk global warm caus frequent heat wave worldwid order respond heat wave enhanc public protect abil europ unit state countri extens carri research heat health earli warn initi achiev good health benefit base heat health earli warn system howev research heat health earli warn still limit china especi health risk popul level base evid base think studi comb research progress heat health earli warn four aspect earli warn indic earli warn model earli warn threshold earli warn rank clarifi key point construct heat health earli warn model rank scheme order provid earli warn technolog rapid develop nation heat heath earli warn china
|
D006358;D000075485
|
T058;T070
|
36,274,613
|
potenti effect mechan research progress extrem temperatur exposur asthma attack asthma one common chronic respiratori diseas incid increas worldwid recent year context climat chang frequenc intens extrem weather event increas larg bodi evid suggest exposur extrem temperatur increas risk asthma attack under mechan trigger asthma attack still unclear studi aim systemat review research progress associ extrem temperatur asthma attack elucid synergist effect extrem temperatur indooroutdoor environ individu vulner asthma attack addit review discuss potenti mechan asthma attack trigger extrem temperatur highlight import role immun regul neuroregul inflammatori respons asthma induc extrem temperatur moreov propos potenti mechan framework explain diseas pathogenesi asthma induc interact extrem temperatur environment factor order provid scientif basi address advers impact extrem weather event climat chang
|
D001249
|
T047
|
36,274,612
|
comparison time seri case crossov analys environment epidemiolog time seri case crossov two main studi design environment epidemiolog howev due differ design principl model construct two analys result two analys may consist herein examin short term effect cold spell cardiovascular mortal nanj use time seri case crossov analys aim provid basi select appropri research design environment epidemiolog
|
D018592
|
T062
|
36,274,611
|
correl analysi drought outpati visit diarrhea children age lanzhou citi tianshui citi gansu provinc studi data pediatr diarrhea clinic gansu provinci matern child health hospit januari decemb tianshui first hospit januari decemb collect standard precipit index spi meteorolog drought composit index mci use drought indic quasi poisson general addit model use analyz correl drought pediatr diarrhea outpati visit studi period dri day lanzhou citi tianshui citi day accord spi day accord mci respect case diarrhea children age year gansu provinci matern child health hospit tianshui first hospit respect mci spi spi base month precipit negat correl number pediatr diarrhea outpati compar non drought period spi show strongest correl middl drought pediatr diarrhea outpati increas ci ci lanzhou citi tianshui citi respect accord mci outpati diarrhea tianshui children increas ci due extrem drought
|
D010045;D003967
|
T184;T101
|
36,274,610
|
north south differ relationship cold spell mortal risk cardiovascular diseas china object analyz north south differ relationship cold spell mortal risk cardiovascular diseas china method time seri analysi method use collect daili count cardiovascular mortal data meteorolog data pm concentr cold season novemb march follow year januari decemb district counti china non constrain distribut lag linear model use analyz relationship cold spell mortal risk cardiovascular diseas north south differ china result mean daili averag temperatur cold season district counti mean daili averag relat humid mean daili averag pm concentr gm averag cold spell day counti day per year mean daili averag temperatur cold spell day q q averag daili number cardiovascular diseas death countydistrict case q q case percentag chang ci south lag higher north percentag chang ci lag north mortal risk year old relat low among three age group percentag chang ci lag south mortal risk year old relat high among three age group percentag chang ci lag conclus mortal risk cardiovascular diseas caus cold spell south higher north china risk peak occur earlier south
|
D002318
|
T047
|
36,274,609
|
intraseason variat associ cold temperatur mortal risk shandong provinc object explor intraseason variat mortal risk cold temperatur exposur shandong provinc method mortal data shandong provinc collect caus death surveil system shandong center diseas control prevent basic inform main includ date death age gender educ level caus death home address etc daili meteorolog data china meteorolog data network main includ grid coordin data latitud longitud daili averag temperatur daili averag relat humid cold season novemb februari first two month earli cold season last two month late cold season extrem cold temperatur defin th percentil temperatur rang cold season time stratifi case crossov design distribut lag non linear model analyz associ temperatur mortal associ extrem low temperatur mortal differ lag day cold season compar intraseason differ earli novemb decemb late januari februari cold season result temperatur rang shandong provinc cold season p extrem low temperatur averag daili temperatur earli cold season temperatur late cold season averag daili relat humid earli cold season late cold season studi includ death cold season shandong provinc male case age year death due circulatori diseas death due respiratori diseas result dlnm show cumul extrem low temperatur four month cold season ci optim temperatur refer cumul valu earli late cold season ci ci respect p lag effect last conclus intraseason variat associ cold temperatur mortal risk shandong provinc mortal risk relat cold temperatur late cold season higher earli cold season
|
D003080;D006358
|
T070
|
36,274,608
|
time seri studi associ ambient temperatur daili outpati visit eczema huizhou citi object explor impact environment temperatur exposur eczema visit method eczema clinic data januari decemb collect huizhou dermatolog hospit data meteorolog factor averag daili temperatur relat humid period deriv meteorolog station guangdong provinci climat center distribut lag nonlinear model dlnm use assess lag effect environment temperatur exposur eczema natur smooth spline function use control nonlinear confound humid result eczema outpati visit huizhou dermatolog hospit within four year averag visit per day relationship daili averag temperatur number visit non linear u shape risk eczema increas everi decreas low temperatur increas everi increas high temperatur effect high temperatur greater low temperatur case eczema outpati visit attribut low temperatur attribut number eczema outpati visit due high temperatur attribut number conclus high temperatur low temperatur associ increas risk eczema
|
D000397;D004485;D000393
|
T131;T047;T069;T080
|
36,274,607
|
assess diseas burden relat non optim temperatur across china object estim excess mortal attribut non optim ambient temperatur china method mortal data meteorolog data counti collect simul quantit exposur respons relationship temperatur mortal use distribut lag nonlinear model time seri studi number non optim temperatur relat excess death assess spatial distribut explor result averag case caus death per day per counti averag daili temperatur daili averag relat humid daili averag concentr gm daili averag pm concentr gm exposur respons curv daili averag temperatur caus mortal show u shape theoret minimum mortal temperatur mmt correspond minimum number death temperatur higher mmt heat relat health effect increas temperatur rise temperatur lower mmt cold relat effect increas temperatur decreas attribut fraction af death caus non optim temperatur ci af death caus cold effect heat effect ci ci respect excess death non optim temperatur could attribut low temperatur number excess death caus non optim temperatur main show decreas trend east west relat high east china heilongjiang provinc northeast china excess death caus low temperatur guangdong provinc south china excess death caus high temperatur conclus non optim temperatur signific impact health caus consider burden diseas china obvious spatial heterogen
|
D017281;D005334
|
T184;T080
|
36,274,606
|
grave concern preval monkeypox virus monkeypox zoonosi caus monkeypox virus monkeypox virus belong orthopoxvirus genus poxvirida famili regard import orthopoxvirus infect human be extinct smallpox sinc first human monkeypox case report democrat republ congo monkeypox becom endem central west african may juli monkeypox broken mani countri monkeypox case detect countri region moreov human human transmiss occur attract high global attent monkeypox virus discov year understand research natur host epidemiolog characterist treatment still relat limit therefor studi analyz epidem situat possibl caus outbreak futur key research direct put forward countermeasur provid scientif basi prevent control monkeypox
|
D045908;D011213
|
T047
|
36,274,605
|
basic immun vaccin fundament booster immun guarante booster immun public health valu booster immun follow vaccin period vaccin primari immun schedul order maintain immun certain pathogen articl immunolog mechan booster immun elabor effect public health valu booster immun common vaccin discuss subsequ three hot issu general concern booster immun address public health viewpoint primari immun vaccin fundament booster immun guarante emphas rais awar import necess booster immun well provid scientif evid vaccin immun practic
|
D011634;D014765
|
T129;T121;T091
|
36,274,604
|
thought suggest co administr season influenza vaccin covid vaccin context global pandem covid epidem intens epidem characterist infect risk influenza present new featur covid influenza simultan emerg mani region world covid influenza similar term transmiss mode clinic symptom aspect also similar mechan influenza virus novel coronavirus cell time feasibl signific good job prevent control covid influenza paper discuss relev strategi measur joint prevent control influenza novel coronavirus aspect influenza vaccin prevent co infect simultan vaccin influenza vaccin novel coronavirus vaccin etc put forward correspond thought suggest order provid scientif support formul strategi season influenza vaccin novel coronavirus vaccin
|
D007252;D007251;D000086382
|
T129;T121;T067;T109;T047
|
36,274,603
|
expert consensus diagnosi treatment prevent allerg diseas part allerg diseas main type allerg reaction mediat ige involv multipl organ system whole bodi run person whole life genet suscept sinc hospit china independ allergi depart consensus establish multidisciplinari expert provid guidanc diagnosi treatment prevent allerg diseas articl first part consensus includ definit term epidemiolog pathogenesi diagnosi concomit diseas preval allerg diseas increas rapid patient get younger bring serious harm innat immun hygien hypothesi microecolog imbal flora imbal air pollut involv diseas diagnosi made accord typic medic histori famili histori symptom sign allergen detect auxiliari examin etc allergen must test often accompani chronic sinus secretori otiti media snore chronic obstruct pulmonari diseas etc
|
D007073;D006967
|
T129;T046;T116
|
36,274,602
|
technic guidelin season influenza vaccin china influenza acut respiratori infecti diseas caus influenza virus serious affect human health influenza virus frequent antigen drift facilit escap pre exist popul immun lead rapid spread annual season epidem influenza outbreak occur crowd set school kindergarten nurs home season influenza epidem caus million sever case respiratori diseas relat death worldwid everi year pregnant women infant adult year older individu comorbid under medic condit highest risk sever ill death influenza given ongo covid pandem provinc southern china summer peak influenza sar cov may co circul influenza respiratori virus upcom winter spring influenza season annual influenza vaccin effect way prevent influenza reduc influenza relat sever ill death reduc harm caus influenza relat diseas use medic resourc current approv influenza vaccin china includ trival inactiv influenza vaccin iiv quadrival inactiv influenza vaccin iiv trival live attenu influenza vaccin laiv iiv produc split virus vaccin subunit vaccin iiv produc split virus vaccin laiv live attenu virus vaccin except jurisdict china influenza vaccin non immun program vaccin voluntarili self paid china cdc issu technic guidelin season influenza vaccin china everi year past year new research evid publish home abroad better guid prevent control influenza vaccin china nation immun advisori committe niac influenza vaccin technic work group updat revis technic guidelin latest research progress technic guidelin season influenza vaccin china new version updat five key area new research evid especi research conduct china ad includ new estim burden influenza diseas assess influenza vaccin effect safeti analys cost effect influenza vaccin polici measur influenza prevent control issu govern past year influenza vaccin approv market china year composit trival quadrival influenza vaccin northern hemispher influenza season recommend influenza vaccin influenza season guidelin recommend vaccin clinic provid influenza vaccin servic peopl age month will vaccin contraind influenza vaccin adult year co administr covid inactiv influenza vaccin separ arm accept regard immunogen reactogen peopl year old least day influenza vaccin covid vaccin guidelin express prefer influenza vaccin type manufactur approv age appropri influenza vaccin use minim harm influenza limit impact effort prevent control covid china technic guidelin recommend prioriti vaccin follow high risk group upcom influenza season healthcar worker includ clinic doctor nurs public health profession quarantin profession volunt staff provid servic support larg event peopl live nurs home welfar home staff take care vulner risk individu peopl work high popul densiti set includ teacher student kindergarten primari secondari school prison prison staff peopl high risk influenza includ adult year age children month age individu comorbid under medic condit famili member caregiv infant month age pregnant women children month year age receiv inactiv influenza vaccin first time receiv two dose inter dose interv week children previous receiv influenza vaccin anyon year older need one dose laiv recommend singl dose regardless previous influenza vaccin vaccin begin soon influenza vaccin becom avail prefer complet onset local influenza season repeat influenza vaccin singl influenza season recommend vaccin clinic provid immun servic throughout epidem season pregnant women receiv inactiv influenza vaccin stage pregnanc guidelin intend use staff cdcs healthcar worker matern child care institut immun clinic staff member work influenza control prevent guidelin updat period new evid becom avail
|
D007252;D007251;D000086382;D009975
|
T129;T121;T067;T109;T005;T047
|
36,274,601
|
strengthen scientif technolog support health adapt action climat chang doubl carbon goal global climat chang process acceler china face great challeng urgent carri scientif studi aim major need health adapt action climat chang doubl carbon target special issu climat chang health highlight report china latest scientif find field health risk non optim temperatur drought ultraviolet radiat meteorolog factor cold spell china clarifi research method health risk earli warn heat wave summar futur research need elucid scientif evid impact meteorolog factor extrem weather event popul health china systemat focus innov develop technic method tool health risk earli warn model acceler transform applic relev scientif technolog achiev china provid scientif technolog support health adapt action climat chang doubl carbon goal
|
D057231;D002244
|
T121;T196;T070
|
36,274,600
|
imag cerebrospin fluid featur two case lymphomatosi cerebri articl report clinic experi diagnosi treatment two patient lymphomatosi cerebri case femal age year old case male age year old progress cognit impair main clinic manifest patient brain magnet reson imag mri suggest leukoencephalopathi patchi mass enhanc cerebr blood flow reduc perfus imag one patient brain biopsi confirm diffus larg b cell lymphoma case concentr interleukin cerebrospin fluid csf two patient signific increas howev result csf flow cytolog negat current studi suggest interleukin csf import biolog indic diagnosi lymphomatosi cerebri csf flow cytometri may help moreov cerebr hypoperfus present patient lymphomatosi cerebri
|
D016753;D016403
|
T129;T191;T116
|
36,274,599
|
effect analysi refractori esophag strictur endoscop mucos dissect earli esophag cancer treat endoscop radiotomi combin local inject triamcinolon acetonid refractor esophag stenosi endoscop submucos dissect earli esophag carcinoma difficult clinic problem verifi effect endoscop radial incis combin local triamcinolon inject treat refractori esophag stenosi retrospect analyz patient diagnos refractori esophag strictur endoscop mucos dissect earli esophag cancer studi male femal patient age year mean age year perform endoscop radial incis thick point scar strictur inject triamcinolon local result show safe effect follow show esophag stenosi occur advers reaction hemorrhag perfor tumor recurr triamcinolon allergi occur
|
D004940;D004938
|
T047;T191
|
36,274,598
|
characterist regulatori mechan lipid metabol remodel malign transform glioma associ macrophag object observ lipid metabol characterist tumor associ macrophag tam malign transform glioma micro environ analyz biolog phenotyp chang regulatori mechan inhibit lipid metabol remodel method twelv male balbc mice week use studi macrophag deriv mous bone marrow malign transform macrophag tm tm clone model glioma stem cell gsc interact vivo vitro intracellular lipid droplet format cellular cholesterol content measur respect tm tm qrt pcr perform detect gene express level relat lipid metabol includ sterol regulatori element bind protein srebp fatti acid synthas fasn hydroxi methylglutar monoacyl coenzym reductas hmg coa simvastatin sim use analyz prolifer immigr invas abil tm tm inhibit lipid metabol differenti express profil mirna sim treatment construct bio informat analysi screen verifi mira target gene sort micro tubul connectin snx associ lipid metabol remodel effect snx regul mir analyz qrt pcr western blot meanwhil biolog phenotyp cholesterol content observ regul mira low densiti lipoprotein receptor ldlr protein level snx knockdown intracellular cholesterol content ldlr knockdown detect respect result number intracellular lipid droplet format tm tm p likewis relat content cholesterol srebp fasn hmg coa signific higher tm tm wel wel wel respect p prolifer rate tm tm decreas respect treatment sim p number migrat cell decreas respect p number invas cell decreas respect p relat intracellular cholesterol content decreas p respect mir screen tm sim target gene analyz verifi snx snx express regul prolifer rate number migrat invas signific decreas mir express p low densiti lipoprotein receptor ldlr express regul knock snx cholesterol content decreas knock ldlr tm tm p conclus malign transform tam undergo lipid metabol remodel character enhanc lipid metabol mir regul ldlr target snx therebi affect lipid metabol malign transform macrophag subsequ inhibit prolifer migrat invas abil precis intervent mir asnxldlr axi could provid experiment basi revers tumor promot micro environ remodel gsc metabol intervent
|
D005910;D035683
|
T123;T191;T114
|
36,274,597
|
safeti feasibl robot assist thoracoscop day surgeri pulmonari nodul retrospect analysi base propens score match object evalu safeti feasibl robot assist thoracoscop day surgeri pulmonari nodul method clinic data patient pulmonari nodul underw robot assist thoracoscop surgeri depart thorac surgeri xiangya hospit central south univers januari june retrospect analyz includ male femal age year patient divid day surgeri group dsg inpati surgeri group isg accord periop manag method propens score match psm perform accord general baselin inform stage tumor surgeri approach tumor posit total patient final includ clinic outcom dsg observ differ incid postop complic treatment relat cost resourc consumpt dsg isg compar subgroup analysi perform accord surgeri method evalu differ dsg isg lobectomi sublobectomi result case dsg eight patient transfer thorac surgeri ward day surgeri discharg rate statist signific differ incid postop complic dsg isg p length stay surgeri period chest drain averag hospit cost drug cost dsg statist signific lower isg vs day vs day vs cni vs cni respect p subgroup analysi statist signific differ incid postop complic drainag volum surgeri vas score discharg dsg isg lobectomi sublobectomi patient result length stay surgeri period chest drain drug cost dsg also signific lower isg p conclus robot assist thoracoscop day surgeri pulmonari nodul safe feasibl advantag short length stay surgeri short period chest drain less averag hospit cost drug cost differ incid postop complic dsg isg
|
D065287;D055613;D008175
|
T061;T033;T191
|
36,274,596
|
impact dosag intraop opioid postop surviv outcom patient pancreat cancer object investig impact dosag intraop opioid postop surviv pancreat cancer patient underw pancreatectomi method clinic data patient pancreat cancer underw pancreatectomi harbin medic univers cancer hospit septemb august retrospect collect dosag intraop opioid medic convert fentanyl equival dose patient divid high dose group fentanyl consumpt mg n low dose group fentanyl consumpt multivari cox analysi show dosag intraop fentanyl associ rfs hr ci p os hr ci p conclus dosag intraop opioid effect rfs os pancreat cancer patient undergo pancreatectomi
|
D000701;D010190
|
T121;T191;T131;T109
|
36,274,595
|
establish qualiti evalu criteria patient medic record cancer pain assess applic effect object establish qualiti evalu criteria patient medic record cancer pain evalu effect applic method evalu criterion establish base delphi method patient medic record cancer pain affili huaian peopl hospit nanj medic univers first weight evalu indic calcul method attribut hierarch model combin techniqu order prefer similar solut ahm topsi patient medic record cancer pain patient group record receiv june assess comprehens second relat close ci valu write qualiti ideal solut calcul well proport evalu indic lack standard third correspond countermeasur adapt base result assess final anoth medic record record receiv octob evalu method differ qualiti medic record proport evalu indic lack standard intervent compar result specif criterion contain integr materi requir medic record document complaint medic histori cancer pain descript previous medic treatment cancer pain regular assess cancer pain document quantit assess document comprehens assess document dynam assess document reason pain medic reason drug usag dosag reason adjust drug varieti dosag prevent advers reaction analges drug document evalu manag advers reaction analges drug document indic establish evalu patient medic record cancer pain proport medic record ci group intervent increas group b intervent differ statist signific p furthermor proport comprehens assess cancer pain lack standard prevent advers reaction quantit evalu dynam assess cancer pain account higher level respect group intervent howev proport record decreas respect group b intervent differ statist signific p conclus specif qualiti evalu criterion establish base delphi method ahm topsi patient medic record cancer pain qualiti medic record improv certain level adapt comprehens evalu intervent patient medic record cancer pain
|
D000072716;D009369
|
T184;T191
|
36,274,594
|
effect cd posit lymphocyt express rate pain control prognosi stage non small cell lung cancer patient cancer pain object investig effect cd posit lymphocyt express rate pain control prognosi stage non small cell lung cancer nsclc patient cancer pain method clinic data stage nsclc patient cancer pain admit affili cancer hospit zhengzhou univers januari decemb retrospect analyz includ male femal male femal ratio averag age year old express rate cd posit lymphocyt peripher blood routin detect admiss express rate cd posit lymphocyt defin cd high express group os time pfs time cd high express group q q month month respect higher cd low express group month month respect p cox multivari analysi show high express cd protect factor affect os hr ci p pfs hr ci p conclus stage nsclc patient cancer pain high express cd posit lymphocyt shorter pain control time less morphin dosag longer os pfs time
|
D002289;D008175;D000072716
|
T184;T191
|
36,274,593
|
analysi concept clinic practic patient control analgesia treatment cancer pain chines medic provid object investig concept clinic practic patient control analgesia pca treatment cancer pain method doctor nurs pharmacist oncolog depart pain depart hospic depart investig use electron questionnair decemb decemb addit basic inform question collect includ current situat cancer pain treatment concept medic staff pca treatment cancer pain clinic practic pca result questionnair medic staff collect hospit provinci administr unit medic staff consid satisfact rate cancer pain control medic staff convinc satisfact rate breakthrough pain control less medic staff consid pca could effect use cancer pain treatment proport medic staff secondari tertiari hospit thought pca applic cancer pain could effect allevi standard non invas drug administr respect higher primari hospit p differ occup proport nurs convinc pca treatment cancer pain increas risk addict drug overdos respect higher doctor respect pharmacist respect p calcul continu infus dose rescu dose pca uniform among differ hospit initi pca hospit insuffici analgesia need adjust time achiev satisfactori analgesia conclus medic staff insuffici cognit pca treatment cancer pain lack unifi guidanc clinic practic therefor urgent need develop expert consensus pca treatment cancer pain
|
D000072716;D009369
|
T184;T191
|
36,274,592
|
doubl edg sword opioid treatment cancer pain hyperalgesia hyperalgesia occult complic treatment cancer pain relat opioid also pertain tumor cancer therapeut drug yet often ignor clinician patient cancer pain treat opioid often sensori abnorm present reduc pain threshold increas sensit nocicept stimuli phenomenon clinic call opioid induc hyperalgesia oih howev due complex pathogenesi lack clinic diagnost criteria pain manag cancer patient still face great challeng therefor articl focus clinic diagnosi pathogenesi prevent treatment hyperalgesia relat cancer pain treatment order provid basi optim use opioid futur
|
D000072716;D009369
|
T184;T191
|
36,274,587
|
lis dynein drive corona compact limit erron microtubul attach kinetochor mitot cell divis requir kinetochor form microtubul attach segreg chromosom control mitot progress via spindl assembl checkpoint prometaphas kinetochor shed domain call fibrous corona microtubul attach form shed mediat part minus end direct motor dynein strip cargo along k fibr microtubul despit essenti littl known dynein strip regul respond attach matur lis also known pafahb conserv dynein regul mutat neurodevelopment diseas lissencephali combin loss function studi high resolut imag separ function mutant defin lis contribut dynein mediat corona strip hela cell cell deplet lis fail disassembl corona show delay metaphas result persist checkpoint activ furthermor find although kinetochor tether lis dynein requir error free microtubul attach contribut lis corona disassembl mediat cytoplasm pool find support idea lis drive dynein function kinetochor ensur corona disassembl prevent chromosom mis segreg
|
D018386;D004398
|
T026;T123;T126;T116
|
36,274,576
|
spontan oxid water microdroplet atmospher implic atom molecular iodin play import role atmospher catalyt deplet ozon oxid gaseous element mercuri known major sourc atmospher photodissoci organoiodin molecul releas alga sea studi show strike result spontan ultrafast oxid evolv water microdroplet present previous unknown sourc atmospher water sea spray cloud microdroplet mass spectrometr evid show spontan generat hydroxyl radic water microdroplet respons oxid taken togeth opin microdroplet chemistri may adopt signific role atmospher redox chemistri
|
D010126;D008628
|
T131;T196;T103
|
36,274,571
|
probe growth metal organ framework x ray scatter vibrat spectroscopi nucleat crystal aris liquid solid phase involv multitud process field rang materi scienc biolog control thermodynam kinet growth advantag help tune format complex morpholog har wide angl x ray scatter vibrat spectroscopi elucid mechan crystal growth metal organ framework co mof within microscop volum enclos capillari attenu total reflect microchip reactor experi reveal molecular structur detail growth process result plane wave densiti function calcul allow identif lattic linker mode form crystal synthesi metal organ framework microscop volum lead monodispers micron size crystal contrast typic observ bulk reaction condit reduct volum reagent within microchip reactor found acceler reaction rate coupl spectroscopi scatter probe reaction microscop volum promis use tool synthet chemist kit understand chemic bond potenti design complex materi
|
D000073396
|
T109
|
36,274,567
|
investig role falx tentorium brain simul strain impact load mild traumat brain injuri mtbi major health concern role falx tentorium ie membran exacerb mtbi conjectur due involv clinic confirm midbrain region recent brain biomechan investig main use comput head model also support hypothesi howev data regard limit toward end use surrog head model investig role membran brain biomechan two differ materi thermoplast polyurethan various elast moduli valu mpa polylact acid elast modulus mpa use examin effect membran stiff brain simul strain head surrog mount hybrid iii neck subject coron sagitt plane rotat use linear impactor system correspond dof head kinemat brain simul strain midcoron midsagitt plane measur result elucid paradigm strain evolut brain simul presenc membran cortic strain decreas wherea strain subcort region either equival increas presenc membran elast modulus membran govern amount strain reduct increas found falx displac constraint stress wave propag domin mechan dictat mechan interact membran brain simul overal result provid novel experiment insight role membran brain deform motiv futurist investig numer subdomain brain injuri biomechan
|
D001930;D001924
|
T037
|
36,274,544
|
research run time risk evalu method base oper scenario data autonom train recent year wit focus research next generat railway risk situat awar safeti decis make enhanc autonomi unman train howev complex environment factor make difficult assess risk train oper thus great necess clear monitor scenario paramet train control system design work infer real time risk collect scenario data paper first clarifi key scenario paramet need collect oper accord concept oper design domain odd oper scenario key paramet depend use deriv dynam bayesian network dbn structur second data probabl uncertainti fuzzi set theori introduc within framework fuzzi dynam reason process present monitor scenario data deviat final case real time risk evalu analysi accid singapor mtr explic demonstr contribut oper data base runtim risk analysi
|
D000063;D011340
|
T041;T037;T067
|
36,274,543
|
incorpor drive volatil measur safeti perform function improv safeti signal intersect percent motor vehicl crash us relat intersect deal crash safeti perform function spfs vital element predict method use highway safeti manual predict crash frequenc potenti reduct due countermeasur base exposur geometr variabl howev role drive behavior factor eg hard acceler declar intersect lead crash explicit treat spfs one way captur drive behavior har connect vehicl data quantifi perform intersect term drive volatil measur ie rapid chang speed acceler accord recent studi drive volatil typic associ higher risk safeti critic event serv surrog drive behavior studi incorpor drive volatil measur develop spfs four leg signal intersect safeti pilot model deploy spmd data contain million basic safeti messag generat connect vehicl har link crash traffic geometr data belong signal intersect ann arbor michigan result show includ drive volatil measur spfs reduc model bias signific enhanc model good fit predict perform technic best result obtain appli bayesian hierarch negat binomi model account spatial correl signal intersect result studi implic practition transport agenc incorpor drive behavior factor develop spfs greater accuraci measur potenti reduc volatil drive
|
D000063;D001334
|
T056;T037;T067
|
36,274,542
|
associ beverag specif alcohol consumpt mortal among road user russia vast bodi literatur suggest relationship alcohol consumpt road traffic fatal despit impress downward trend road traffic fatal russia death rate still unaccept high far fewer studi differenti associ road user type alcohol beverag popul base studi aim estim associ total beverag specif alcohol per capita consumpt apc base offici alcohol sale statist road traffic mortal use polic data number death road user studi cover period employ first order differ linear regress model robust autocorrel consist standard error control level motoris examin possibl evolut phenomenon repeat model separ three consecut period find suggest annual litr increas apc litr pure alcohol associ correspond increas death rate per inhabit unprotect road user motor vehicl occup p p respect beverag specif analysi reveal posit signific associ mortal pedestrian cyclist consumpt strong alcohol beverag p well mortal driver passeng consumpt weaker alcohol beverag primarili beer p various road safeti strategi appli prevent road traffic fatal road user
|
D000063;D000069636
|
T098;T037;T067
|
36,274,530
|
develop generic ultra high pressur gradient liquid chromatographi method develop protocol analysi residu multi class antibiot food product case studi present studi discuss uhplc method develop allow establish ultra high resolut separ gradient mode oper kinet perform limit target analysi complex residu multi class antibiot sampl food product peak capac gradient occup systemat assess differ flow rate gradient durat small particl size core shell particl use studi limit mass transfer contribut band broaden oper high flow rate result high throughput analysi high pressur bar oper lead high resolv power gradient steep domin peak capac generat vs mass transfer resist reach highest possibl resolv power within practic accept analysi time one use coupl column system bar adjust gradient steep correspond coupl four column appli shallow gradient bar led sampl peak capac min allow resolv analyt mixtur compos milk antibiot
|
D000900
|
T121;T195
|
36,274,529
|
mesopor coval organ framework microspher dual phase separ strategi high puriti glycopeptid enrich high perform porous materi ration enrich strategi crucial sampl pretreat process glycoproteom analysi herein report dual phase separ strategi base hydrophob hydrophil mesopor coval organ framework cof microspher high puriti glycopeptid enrich first time cof microspher hydrophob mesopor nm prepar facil method room temperatur post synthesi modif strategi hydrophil mesopor obtain modifi vinyl ligand glutathion gsh hydrophil properti cof microspher enhanc introduct au nanoparticl gsh obtain hydrophil cof microspher denot cof au gsh low abund hydrophil glycopeptid could effici enrich hydrophil cof au gsh microspher low polar solut high abund hydrophob non glycopeptid remov hydrophob cof microspher high polar solut help dual phase separ strategi inher properti cof structur prepar cof microspher show splendid enrich perform glycopeptid includ ultrahigh sensit fmol igg digest extrem high specif igg digestsbsa digest excel size select igg digestsbsaigg larg bind capac mg g igg digest addit total glycopeptid could enrich identifi rat liver digest enrich cof microspher proof concept applic propos strategi success use sampl pretreat process plasma glycoproteom analysi
|
D000073396;D053768
|
T073;T109
|
36,274,520
|
contemporari self reflect practic larg scale survey although self reflect topic appear human comput interact empir data subject often date fragment focus particular use case work sought captur data would help us better understand current use technolog support self reflect broader popul larg scale onlin survey repres sampl internet user unit kingdom n smaller seri follow interview n found regardless recent stress high score scale measur self reflect maintain wider varieti self reflect activ recent month men report access use technolog self reflect activ women women self reflect score usual higher note high self reflector appear spontan experiment use heurist mitig common barrier adapt practic stressor individu appear favour analogu object facilit reflect practic utilis technolog strateg select way
|
D011795
|
T098;T062;T170;T081;T057
|
36,274,511
|
generat human ipsc deriv heart organoid structur function similar heart current due increas demand cultur various organoid mimic organ activ studi despit activ report inform heart organoid hos first function organ still insuffici paramet reproduc heart chamber format organ cardiac cell vascular simul electrophysiolog signal particular sinc heart reflect complex factor necessari develop hos simul depth studi creat self organ hos use human ipsc valid mimicri cardiac structur chamber epicardiummyocardium atriumventricl similar area furthermor mechanicalelectrophysiolog featur verifi multipl analyz inhibit ion channel import hos function due cardiovascular characterist hos maintain vascular vivo transplant conclus studi advantag abl easili close recapitul morphologicalfunct aspect heart
|
D009940;D057026
|
T025;T024
|
36,274,478
|
analysi phospholipid triacylglycerol intraven lipid emuls intraven lipid emuls ile use parenter nutrit provid vital sourc essenti fatti acid concentr energi patient unabl absorb nutrient via digest track common use treat local non local anesthet toxic lipophil drug overdos ile compos natur lipid composit natur lipid vari base sourc lipid suscept hydrolyt degrad time result various lipid degrad product lysophosphatidylcholin lps affect actual composit nutrient formul result identif quantif lipid compon includ degrad product ile crucial qualiti control studi lipid differ batch ile intralipid separ identifi use uhplc esi qtof system simlipid high throughput lipid identif softwar lipid identifi phospholipid pls other triacylglycerol tag phospholipid detect phosphatidylcholin pc lysophosphatidylcholin lpc total lpcs pcs phosphoethanolamin pes sphingomyelin sm identifi lpcs concentr chang manufactur date storag time uhplc method enabl identif quantif lipid decomposit product complex ile emuls mixtur singl minut chromatograph run
|
D005217;D008244
|
T121;T109
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.